ABAriane Blum

Ariane Blum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ariane Blum has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Paul Molens

    Institut d'oncologie/développement Albert Bonniot de Grenoble INSERM : U823CHU GrenobleEFSUniversité Joseph Fourier - Grenoble IInstitut Albert Bonniot, BP170, 38042 Grenoble Cedex 9,FR

    3 shared publications
  • Laurence Chaperot

    Université Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), Team Translational Immunology and Immunotherapy in Chronic Disease Grenoble France

    3 shared publications
  • Joël Plumas

    Institut d'oncologie/développement Albert Bonniot de Grenoble INSERM : U823CHU GrenobleEFSUniversité Joseph Fourier - Grenoble IInstitut Albert Bonniot, BP170, 38042 Grenoble Cedex 9,FR

    2 shared publications
  • Dominique Plantaz

    1 shared publication
  • Gabrielle Lui

    Department of Research and Development, Etablissement Français du Sang Rhône-Alpes Grenoble , La Tronche

    1 shared publication
  • Joël Plumas

    Department of Research and Development, Etablissement Français du Sang Rhône-Alpes Grenoble , La Tronche

    1 shared publication

Latest Publications

  • TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN

    by Jérémy Di Domizio, Ariane Blum, Maighread Gallagher-Gambarelli, Jean-Paul Molens, Laurence Chaperot, Joël Plumas

    On recognition of influenza virus (Flu) by TLR7, plasmacytoid dendritic cells (pDCs) produce type I IFN in significant amounts. Synthetic TLR7 ligands induce the maturation of pDCs, as evidenced by the expression of costimulatory molecules and the production of proinflammatory cytokines; however, they induce only low-level production of IFN-α. To dissect the TLR7 signaling in pDCs and how these different profiles are induced, we studied the effects of 2 TLR7 ligands (Flu and CL097) on the activation of blood-isolated pDCs and the human GEN2.2 pDC cell line. Type I IFN production by pDCs correlates with differential interferon regulatory factor 7 (IRF7) translocation into the nucleus induced by the 2 TLR7 ligands. Surprisingly, with both activators we nevertheless observed the rapid expression of the IFN-inducible genes mxa, cxcl10, and trail within 4 hours of stimulation. This expression, controlled by STAT1 phosphorylation, was independent of type I IFN. STAT1 activation was found to be strictly dependent on the PI3K-p38MAPK pathway, showing a new signaling pathway leading to rapid expression of IFN-inducible genes after TLR7 triggering. Thus, pDCs, through this unusual TLR7 signaling, have the capacity to promptly respond to viral infection during the early phases of the innate immune response.


  • Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells

    by Ariane Blum, Laurence Chaperot, Jean-Paul Molens, Vincent Foissaud, Dominique Plantaz, Joël Plumas


  • Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells

    by Laurence Chaperot, Ariane Blum, Olivier Manches, Gabrielle Lui, Juliette Angel, Jean-Paul Molens, Joël Plumas

    Among dendritic cells, plasmacytoid dendritic cells (PDC) represent a functionally distinct lineage. Regarding innate immunity, PDC secrete large amounts of type I IFN upon viral exposure or stimulation by microbial products such as unmethylated CpG-motif containing oligo-DNA due to their selective expression of TLR7 and TLR9. We asked whether they could acquire cytotoxic functions during the early phases of infection or after activation with TLR7 or TLR9 agonists. In the present study, we describe a human PDC cell line called GEN2.2, derived from leukemic PDC, that shares most of the phenotypic and functional features of normal PDC. We show that after contact with the influenza virus, GEN2.2, as well as normal PDC, acquires TRAIL and killer activity against TRAIL-sensitive target cells. Moreover, we show that activation of GEN2.2 cells by CpG-motif containing oligo-DNA or R848 also induces TRAIL and endows them with the ability to kill melanoma cells. Therefore, PDC may represent a major component of innate immunity that could participate to the clearance of infected cells and tumor cells. This phenomenon could be relevant for the efficacy of TLR7 or TLR9 agonists in the therapy of infectious disease and cancer.